An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 315 participants.

Also called NCT01078675

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 315 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01078675
Other papers using this trial's data
  • Hypercholesterolemia and reduced HDL-C promote hematopoietic stem cell proliferation and monocytosis: studies in mice and FH children Atherosclerosis, 2013-07 DOI, PubMed 23684512, PMC3691284 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Canada, Netherlands, Norway (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01078675. Non-randomized; no masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2015-02-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia
Condition
Familial Hypercholesterolaemia
Intervention (Drug)
rosuvastatin calcium
Intervention (Drug)
rosuvastatin calcium
Intervention (Drug)
rosuvastatin calcium
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01078675
Content hash
c17955f7f3fb6cb3471fe5cda8d82611ba664649a681b8119b537394dda8ecfd